BioInformant

Your Global Leader in Stem Cell Market Research

MENUMENU
  • Blog
  • Stem Cells
    • iPS Cells
    • MSCs
    • HSCs
    • Adipose SCs
    • Neural Stem Cells
  • Cell Therapy
    • COVID-19
    • CAR-T
    • Cord Blood
  • Exosomes
  • Interviews
  • News
    • Press Releases
    • Job Posts
  • Shop
    • Products
    • Submit PR
    • Advertise
  • About
    • Testimonials
    • Story
    • Guarantee
    • Contact
  • Home
  • Blog
    • Stem Cells
      • HSCs
      • iPS Cells
      • MSCs
      • Neural Stem Cells
      • Adipose SCs
    • Exosomes
    • Cell Therapy
      • CAR-T
    • Cord Blood
    • Stem Cell News
    • Interviews
  • COVID-19
  • Shop
  • Submit PR
  • Company
    • Advertise
    • Testimonials
    • Story
    • Job Posts
    • Guarantee
    • Privacy Policy
    • Contact
Home » direct cell reprogramming

The Future of Stem Cell Therapeutics – Balancing Safety and Efficacy

January 11, 2021 By Cade Hildreth (CEO) 4 Comments

Safety Chart | The Future of Stem Cell Therapeutics – Balancing Safety and Efficacy

What do we know of the safety and efficacy of stem cell therapeutics? Over 50 years have passed since the discovery of hematopoietic stem cells (bone marrow transplantation to cure diseases such as leukemia), over 20 years since the discovery of human embryonic stem cells (hESC), and 15 years since the discovery of induced pluripotent stem cells (iPS cells). There are also thousands of stem cell trials ongoing in clinics globally.

Despite this experience, what do we actually know about the safety and efficacy of stem cell therapeutics?

Stem Cell Therapeutics and Safe Practice

In this article:

    • Safety and Efficacy Issues with Stem Cell Therapies
    • How do Different Stem Cell Therapies Stack up Against these Critical Factors?
    • Direct Cell Reprogramming for Highest Safety and Efficacy

Safety and Efficacy Issues with Stem Cell Therapies

In this novel and increasingly complex stem cell space, it is perhaps a timely question to ask, especially since the regulatory assessment criteria designed for conventional medicines are not directly applicable for stem cell therapy. [Read more…]

Filed Under: HSCs, iPS Cells, MSCs, Neural Stem Cells, Stem Cells Tagged With: direct cell reprogramming, stem cell therapy

Direct Cell Reprogramming: What Is It and How Does It Work?

February 26, 2020 By Cade Hildreth (CEO)

Direct Cell Reprogramming Diagram

There has been tremendous activity over the last decade in the development of stem cells therapeutics, which have relied on stem cell differentiation protocols, as well as techniques for direct cell reprogramming. Today, there are over 5,400 stem cell trials registered on ClinicalTrials.gov and publications have increased dramatically in recent years, demonstrating the rapidly growing interest of the scientific community.

However, for all its promise, stem cells are yet to deliver on this therapeutic potential, and this failure appears due to various technical challenges that still need to be overcome. [Read more…]

Filed Under: Stem Cells Tagged With: direct cell reprogramming, iPSC

Mogrify Raises $3.7M for Direct Cell Reprogramming and Appoints Dr. Disley CEO

February 25, 2019 By Cade Hildreth (CEO)

Mogrify - Cell Mogrify Ltd

MogrifyMogrify (Cell Mogrify Ltd) is a private biotechnology company has developed a direct cellular conversion technology to allow for the transformation (transmogrification) of any mature human cell type into any other – without going through a pluripotent stem cell- or progenitor cell-state. [Read more…]

Filed Under: Stem Cell News, Stem Cells Tagged With: direct cell reprogramming, Mogrify

Let’s Get Social

  • Facebook
  • Twitter
  • Instagram
  • Pinterest
  • LinkedIn

Nanocellect

Marathon Products

Menu
  • Blog
  • Stem Cell News
    • Press Releases
  • Stem Cells
    • HSCs
    • iPS Cells
    • MSCs
    • Neural Stem Cells
    • Adipose SCs
  • Exosomes
  • Cell Therapy
    • CAR-T
  • Cord Blood
  • Interviews

Cart

Top Rated Products

  • US Cord Blood and Cord Tissue Storage Rates Rates of U.S. Cord Blood and Cord Tissue Storage - Historical and Projected
    Rated 0 out of 5
    $197
  • Job Posting on BioInformant Job Posting on BioInformant.com - Your Perfect Hire Is In Our Audience
    Rated 0 out of 5
    $297
  • BioInformant Audience Reach BioInformant's Audience with Your Press Announcement
    Rated 0 out of 5
    $397 $297
My Tweets

BioInformant's World-Class Clients

  • Submit Press Release
  • Advertise
  • Privacy and Terms

Copyright © 2021 · BIOINFORMANT, Your Global Leader in Stem Cell Market Research

| Email: [email protected] | Phone: 703-859-7617 |

800 Corporate Drive, Suite 301, Stafford, VA 22554, United States

Disclaimer: All statements made on this website are NOT expressed as medical claims or advice. They are not intended to diagnose, treat, cure or prevent any disease or condition. If you have a health condition or concern, consult your physician or health care provider.